Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement.

Safety 111

Safety Medical Marketing Sales 111

PharmaTimes

MARCH 28, 2023

Clinical trial involves patients with liver cirrhosis and hepatic encephalopathy

Patients 87

Patients 87

Pharmaceutical Technology

JANUARY 8, 2024

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

52

52

Pharmaceutical Technology

OCTOBER 3, 2023

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

Biopharma 52

Biopharma 52

European Pharmaceutical Review

NOVEMBER 9, 2022

GSK has announced study results from its Phase IIb trial ( NCT04449029 ) of bepirovirsen for chronic hepatitis B (CHB), indicating that the antisense oligonucleotide therapy could help treat CHB independently or in combination with nucleoside/nucleotide analogues (NAs). Further data on the chronic hepatitis B clinical trial.

Safety 87

Safety Patients Medicine Leads 87

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. It will also evaluate ENGERIX-B, a GSK-manufactured three-dose hepatitis B vaccine series.

Patients 76

Patients Food and Drug Administration Side effects Food 76

Pharmaceutical Technology

DECEMBER 20, 2023

VTP-300 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Hepatitis B.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

40

40

Pharmaceutical Technology

OCTOBER 3, 2023

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

Biopharma 40

Biopharma 40

Pharmaceutical Technology

NOVEMBER 3, 2022

The US Food and Drug Administration (FDA) has granted approval for the supplemental new drug application (sNDA) of Gilead Sciences ’ Vemlidy (tenofovir alafenamide) to treat chronic hepatitis B virus (HBV) infection in paediatric patients.

Food and Drug Administration 52

Food and Drug Administration FDA Physicians Food 52

European Pharmaceutical Review

AUGUST 23, 2022

The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. Participants received one combination of hepatitis C medications: including glecaprevir and pibrentasvir (GLE/PIB); ledipasvir and sofosbuvir (LDV/SOF); or sofosbuvir and velpatasvir (SOF/VEL). .

Food and Drug Administration 72

Food and Drug Administration Pharmacology Prospecting Medical 72

Pharmacy Times

FEBRUARY 12, 2024

Bepirovirsen is a triple action investigational antisense oligonucleotide and is being evaluated in the B-Well phase 3 clinical trial program for the treatment of chronic hepatitis B.

FDA 26

FDA 26

European Pharmaceutical Review

MARCH 24, 2023

This treatment decreases hepatic steatosis and circulating lipids. He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space. Data from clinical trials to-date suggests that pegozafermin could reduce hepatic fat and fibrosis.

Medical 86

Medical Side effects Safety Pharmaceutical 86

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. The post UNC team discovers interactions vital for hepatitis A virus replication appeared first on Pharmaceutical Technology.

Recruitment 52

Recruitment Medicine Pharmaceutical 52

Clarivate

NOVEMBER 13, 2023

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. The purpose of clinical trials is to understand the efficacy and safety of treatments for the patients who need them.

Patients 52

Patients Food and Drug Administration FDA Safety 52

European Pharmaceutical Review

JUNE 27, 2023

Diabetes cell therapy manufacture In Vertex’s first clinical programme, VX-880, recently released data showed all six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide). Operated by Lonza, the 130,000 square foot facility is anticipated to create up to 300 new jobs at peak capacity.

Manufacturing 95

Manufacturing Pharmaceutical Patients 95

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData, Phase I drugs for Liver Failure (Hepatic Insufficiency) does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

Medicine 40

Medicine Distribution Pharmaceutical products Networking 40

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. By adding an additional pipeline targeting oncology and inflammation diseases, the company expects that the deal will complement its existing clinical development priorities.

Medicine 52

Medicine Marketing 52

pharmaphorum

JULY 26, 2022

The Hepatitis B (HBV) vaccine and human papillomavirus (HPV) vaccines are key examples. For Christopher Oelkrug, Director of Business Development for Advanced Clinical, it’s an exciting time to investigate the clinical efficacy of therapeutic cancer vaccines.

Training 52

Training Patients 52

European Pharmaceutical Review

SEPTEMBER 20, 2022

Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression. Zuranolone was generally well-tolerated with a safety profile consistent with prior clinical studies. Can Hepatitis C drugs reduce symptoms of PTSD?

Safety 88

Safety Patients Leads Pharmaceutical 88

European Pharmaceutical Review

FEBRUARY 23, 2023

Meg Doherty, Director of WHO’s Global HIV, Hepatitis and Sexually Transmitted Infections Programmes in Geneva welcomed the results of the D2EFT study. For more than three million people living with HIV worldwide for whom first-line HIV treatment does not work, there is now evidence to support a range of treatment options.

Medical 93

Medical Healthcare Healthcare Management 93

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Renal Cell Carcinoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Pharmaceutical 40

Pharmaceutical 40

World of DTC Marketing

AUGUST 21, 2020

Evidence that obese people have a blunted response to common vaccines was first observed in 1985 when obese hospital employees who received the hepatitis B vaccine showed a significant decline in protection 11 months later that was not observed in non-obese employees. And it’s getting worse.

Insurance 238

Insurance Physicians Healthcare Healthcare 238

Clarivate

APRIL 19, 2024

6] HCC is a type of FLL; however, FLLs also encompass other malignant lesions, such as intrahepatic cholangiocarcinoma and hepatic metastasis, as well as benign lesions such as hepatic haemangioma and focal nodular hyperplasia. ACG clinical guideline: the diagnosis and management of focal liver lesions. Eur J Cancer. Front Phys.

Medical 59

Medical Patients Specialization Healthcare 59

Pharmaceutical Technology

JUNE 13, 2023

Patients with moderate hepatic impairment or who are taking moderate CYP3A4 [the main human enzyme responsible for phase I metabolism] inhibitors, may take 25mg once each night. Somnolence and headache are the most frequently reported adverse reactions observed in clinical trials.

Patients 52

Patients Marketing Management Leads 52

Pharmaceutical Technology

JULY 22, 2022

Muge Cevik’s tweet on the rise of unusual paediatric hepatitis cases. Muge Cevik, a clinical scientist, shared an article around the mystery of viral hepatitis cases in children. Retweets: 118. Username: Muge Cevik. Twitter handle: @mugecevik. Likes: 382. Retweets: 125. Helen Branswell’s tweet on the first US monkeypox case.

Pharmaceutical 52

Pharmaceutical Medicine Safety 52

Pharmaceutical Technology

SEPTEMBER 20, 2022

Genfit has signed an exclusivity agreement for the acquisition of all the share capital and voting rights of Versantis, a Switzerland-based clinical-stage biotechnology firm, in a deal totalling $109m (Sfr105m). Versantis focuses on unmet liver ailment needs.

Biopharma 59

Biopharma Sales Management Pharmaceutical 59

Pharmaceutical Technology

NOVEMBER 4, 2022

According to the data from a Phase III efficacy clinical trial, the seroconversion rate was found to be 97.1% In the future, we will continue to work on more clinical trials, registrations and approvals for vaccines worldwide, to offer the world high-quality vaccines and ensure the accessibility and affordability of these public goods.”.

Specialization 52

Specialization Government Pharmaceutical 52

pharmaphorum

JUNE 23, 2022

Enanta has a long heritage in the development of antiviral compounds, working with AbbVie on therapies for hepatitis C virus (HCV) infection including Viekira Pak (paritaprevir/ritonavir/ombitasvir/dasabuvir) and Mavyret/Maviret (glecaprevir/pibrentasvir).

Distribution 52

Distribution Pharma Sales Pharmaceutical 52

pharmaphorum

SEPTEMBER 29, 2022

CyberLiver’s chief executive Ravi Kumar said the breakthrough designation will help the company expedite the development of the DTx and move forward with finding partnerships to bring it into clinical use. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Manufacturing 40

Manufacturing Networking Marketing Medicine 40

Medgadget

AUGUST 23, 2022

Despite advances in identifying and treating viral hepatitis, the rise of type 2 diabetes, metabolic syndrome and associated non-alcoholic fatty liver disease (NAFLD) have substantially increased the burden of chronic liver diseases worldwide. Today, it is estimated that 1.5

Training 76

Training Patients Leads FDA 76

pharmaphorum

AUGUST 3, 2022

Gilead is no stranger to managing ‘boom and bust’ products – think back to the spectacular rise and swift fall of its hepatitis C virus (HCV) therapies a few years ago – and the shift to a more diversified business under chief executive Daniel O’Day has softened the latest blow.

Sales 91

Sales Management Marketing 91

Pharmaceutical Technology

APRIL 21, 2023

In a statement emailed to Endpoints News , AstraZeneca (AZ) disclosed intentions to terminate its clinical program for its daily glucagon-like peptide-1 receptor glucagon co-agonist (GLP-1RA/GCGR) cotadutide, in favour of focusing on the development of AZD9550, its once-weekly injectable GLP-1RA/GCGR.

Marketing 52

Marketing Patients Recruitment Consulting 52